Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does UPADACITINIB Cause Blood creatine phosphokinase increased? 122 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 122 reports of Blood creatine phosphokinase increased have been filed in association with UPADACITINIB (Rinvoq). This represents 0.2% of all adverse event reports for UPADACITINIB.

122
Reports of Blood creatine phosphokinase increased with UPADACITINIB
0.2%
of all UPADACITINIB reports
2
Deaths
38
Hospitalizations

How Dangerous Is Blood creatine phosphokinase increased From UPADACITINIB?

Of the 122 reports, 2 (1.6%) resulted in death, 38 (31.1%) required hospitalization, and 3 (2.5%) were considered life-threatening.

Is Blood creatine phosphokinase increased Listed in the Official Label?

Yes, Blood creatine phosphokinase increased is listed as a known adverse reaction in the official FDA drug label for UPADACITINIB.

What Other Side Effects Does UPADACITINIB Cause?

Pain (4,444) Arthralgia (3,815) Drug ineffective (3,384) Covid-19 (2,978) Rheumatoid arthritis (2,730) Pain in extremity (2,353) Fatigue (2,153) Fall (2,081) Surgery (2,037) Therapy interrupted (1,741)

What Other Drugs Cause Blood creatine phosphokinase increased?

ATORVASTATIN (1,491) SIMVASTATIN (895) ROSUVASTATIN (859) QUETIAPINE (663) CLOZAPINE (610) ARIPIPRAZOLE (594) OLANZAPINE (561) DAPTOMYCIN (461) RISPERIDONE (402) EZETIMIBE (350)

Which UPADACITINIB Alternatives Have Lower Blood creatine phosphokinase increased Risk?

UPADACITINIB vs URAPIDIL UPADACITINIB vs UREA UPADACITINIB vs URIDINE TRIACETATE UPADACITINIB vs UROFOLLITROPIN UPADACITINIB vs URSODIOL

Related Pages

UPADACITINIB Full Profile All Blood creatine phosphokinase increased Reports All Drugs Causing Blood creatine phosphokinase increased UPADACITINIB Demographics